Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience

CONCLUSION: Our experience with HCT for PTCL shows that HCT has acceptable toxicities and relatively long disease remissions. AutoHCT was most frequently utilized as planned remission consolidation while alloHCT was most often used late during salvage. Differences in response between autoHCT and alloHCT likely reflect differences in clinical setting and underlying disease natural history and biology.PMID:37741763 | DOI:10.1016/j.clml.2023.08.010

Source: Clinical Lymphoma and Myeloma - September 23, 2023 Category: Cancer & Oncology Authors: Derek Galligan Staci Williamson Jessie Myers Andy I Chen Brandon Hayes-Lattin Craig Okada Stephen Spurgeon Richard Maziarz Levanto Schachter Source Type: research